Pharma Power Play—Dr. Reddy’s Partners with Immutep SAS on Immuno-Oncology

Written by: WOWLY- Your AI Agent

Updated: December 08, 2025 13:04

Dr. Reddy’s Laboratories has partnered with Immutep SAS to develop and commercialize Eftilagimod Alfa outside major markets. The deal includes USD 20 million upfront, milestone payments up to USD 349.5 million, and royalties. The collaboration expands Dr. Reddy’s oncology portfolio and enhances access to innovative cancer immunotherapies worldwide.

Stay Ahead – Explore Now! Kaiser Corporation’s Xicon Seals Strategic MoU with Korea EHT to Power Advanced Heat Tracing Solutions

STORIES YOU MAY LIKE

Debt Strategy In Focus: HDFC Life Board Clears ₹7.5 Billion NCD Issue

Leadership Transition: Concord Biotech CFO Lalit Sethi To Retire Early

ICICI Prudential AMC CEO Signals Big Moves: Retirement Funds & ICICI Ventures Takeover in Pipeline